These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 17972923)

  • 1. DNA, but not protein vaccine based on mutated BORIS antigen significantly inhibits tumor growth and prolongs the survival of mice.
    Mkrtichyan M; Ghochikyan A; Loukinov D; Davtyan H; Ichim TE; Cribbs DH; Lobanenkov VV; Agadjanyan MG
    Gene Ther; 2008 Jan; 15(1):61-4. PubMed ID: 17972923
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elicitation of T cell responses to histologically unrelated tumors by immunization with the novel cancer-testis antigen, brother of the regulator of imprinted sites.
    Ghochikyan A; Mkrtichyan M; Loukinov D; Mamikonyan G; Pack SD; Movsesyan N; Ichim TE; Cribbs DH; Lobanenkov VV; Agadjanyan MG
    J Immunol; 2007 Jan; 178(1):566-73. PubMed ID: 17182597
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancement of therapeutic DNA vaccine potency by melatonin through inhibiting VEGF expression and induction of antitumor immunity mediated by CD8+ T cells.
    Baghban Rahimi S; Mohebbi A; Vakilzadeh G; Biglari P; Razeghi Jahromi S; Mohebi SR; Shirian S; Gorji A; Ghaemi A
    Arch Virol; 2018 Mar; 163(3):587-597. PubMed ID: 29149434
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor efficacy of DNA vaccination to the epigenetically acting tumor promoting transcription factor BORIS and CD80 molecular adjuvant.
    Loukinov D; Ghochikyan A; Mkrtichyan M; Ichim TE; Lobanenkov VV; Cribbs DH; Agadjanyan MG
    J Cell Biochem; 2006 Aug; 98(5):1037-43. PubMed ID: 16741971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic effect of programmed cell death protein 1 blockade and secondary lymphoid tissue chemokine in the induction of anti-tumor immunity by a therapeutic cancer vaccine.
    Moeini S; Saeidi M; Fotouhi F; Mondanizadeh M; Shirian S; Mohebi A; Gorji A; Ghaemi A
    Arch Virol; 2017 Feb; 162(2):333-346. PubMed ID: 27699512
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancing DNA vaccine potency by combining a strategy to prolong dendritic cell life with intracellular targeting strategies.
    Kim TW; Hung CF; Boyd D; Juang J; He L; Kim JW; Hardwick JM; Wu TC
    J Immunol; 2003 Sep; 171(6):2970-6. PubMed ID: 12960321
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of a Leishmania hypothetical protein administered as DNA vaccine or recombinant protein against Leishmania infantum infection and its immunogenicity in humans.
    Ribeiro PAF; Dias DS; Lage DP; Costa LE; Martins VT; Tavares GSV; Mendonça DVC; Lima MP; Oliveira JS; Steiner BT; Machado-de-Ávila RA; Roatt BM; Chávez-Fumagalli MA; Menezes-Souza D; Duarte MC; Teixeira AL; Coelho EAF
    Cell Immunol; 2018 Sep; 331():67-77. PubMed ID: 29871740
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic targeting of the active transcription factor XBP1s to dendritic cells potentiates vaccine-induced prophylactic and therapeutic antitumor immunity.
    Tian S; Liu Z; Donahue C; Falo LD; You Z
    Mol Ther; 2012 Feb; 20(2):432-42. PubMed ID: 21934655
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting of the non-mutated tumor antigen HER2/neu to mature dendritic cells induces an integrated immune response that protects against breast cancer in mice.
    Wang B; Zaidi N; He LZ; Zhang L; Kuroiwa JM; Keler T; Steinman RM
    Breast Cancer Res; 2012 Mar; 14(2):R39. PubMed ID: 22397502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant use of the NKT cell agonist alpha-galactosylceramide leads to enhancement of M2-based DNA vaccine immunogenicity and protective immunity against influenza A virus.
    Fotouhi F; Shaffifar M; Farahmand B; Shirian S; Saeidi M; Tabarraei A; Gorji A; Ghaemi A
    Arch Virol; 2017 May; 162(5):1251-1260. PubMed ID: 28120096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elimination of IL-10-inducing T-helper epitopes from an IGFBP-2 vaccine ensures potent antitumor activity.
    Cecil DL; Holt GE; Park KH; Gad E; Rastetter L; Childs J; Higgins D; Disis ML
    Cancer Res; 2014 May; 74(10):2710-8. PubMed ID: 24778415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A MUC1/IL-18 DNA vaccine induces anti-tumor immunity and increased survival in MUC1 transgenic mice.
    Snyder LA; Goletz TJ; Gunn GR; Shi FF; Harris MC; Cochlin K; McCauley C; McCarthy SG; Branigan PJ; Knight DM
    Vaccine; 2006 Apr; 24(16):3340-52. PubMed ID: 16472547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
    Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
    Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Individual analysis of mice vaccinated against a weakly immunogenic self tumor-specific antigen reveals a correlation between CD8 T cell response and antitumor efficacy.
    Rosato A; Zoso A; Milan G; Macino B; Dalla Santa S; Tosello V; Di Carlo E; Musiani P; Whalen RG; Zanovello P
    J Immunol; 2003 Nov; 171(10):5172-9. PubMed ID: 14607917
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improvement in T helper 1-related immune responses in BALB/c mice immunized with an HIV-1 gag plasmid combined with a chimeric plasmid encoding interleukin-18 and flagellin.
    Chen YL; Chen YS; Hung YC; Liu PJ; Tasi HY; Ni WF; Hseuh PT; Lin HH
    Microbiol Immunol; 2015 Aug; 59(8):483-94. PubMed ID: 26094825
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Electroporation as a "prime/boost" strategy for naked DNA vaccination against a tumor antigen.
    Buchan S; Grønevik E; Mathiesen I; King CA; Stevenson FK; Rice J
    J Immunol; 2005 May; 174(10):6292-8. PubMed ID: 15879128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer-testis antigen, BORIS based vaccine delivered by dendritic cells is extremely effective against a very aggressive and highly metastatic mouse mammary carcinoma.
    Mkrtichyan M; Ghochikyan A; Davtyan H; Movsesyan N; Loukinov D; Lobanenkov V; Cribbs DH; Laust AK; Nelson EL; Agadjanyan MG
    Cell Immunol; 2011; 270(2):188-97. PubMed ID: 21641588
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytokine genetic adjuvant facilitates prophylactic intravascular DNA vaccine against acute and latent herpes simplex virus infection in mice.
    Cui FD; Asada H; Jin ML; Kishida T; Shin-Ya M; Nakaya T; Kita M; Ishii M; Iwai M; Okanoue T; Imanishi J; Mazda O
    Gene Ther; 2005 Jan; 12(2):160-8. PubMed ID: 15470476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of adjuvant activity of fractions derived from Agaricus blazei, when in association with the recombinant LiHyp1 protein, to protect against visceral leishmaniasis.
    de Jesus Pereira NC; Régis WC; Costa LE; de Oliveira JS; da Silva AG; Martins VT; Duarte MC; de Souza JR; Lage PS; Schneider MS; Melo MN; Soto M; Soares SA; Tavares CA; Chávez-Fumagalli MA; Coelho EA
    Exp Parasitol; 2015 Jun; 153():180-90. PubMed ID: 25845753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cellular immunotherapy using irradiated lung cancer cell vaccine co-expressing GM-CSF and IL-18 can induce significant antitumor effects.
    Tian H; Shi G; Yang G; Zhang J; Li Y; Du T; Wang J; Xu F; Cheng L; Zhang X; Dai L; Chen X; Zhang S; Yang Y; Yu D; Wei Y; Deng H
    BMC Cancer; 2014 Jan; 14():48. PubMed ID: 24475975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.